ArticleMolecular biology reports2026
SLC25A1 drives lipid metabolic reprogramming promoting liver injury leading to hepatocellular carcinoma.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer metabolism especially lipid metabolic reprogramming is considered one of the most important metabolic processes involved in hepatocellular carcinoma (HCC). Solute carrier family 25 member A1 (SLC25A1) is a citrate transporter present in mitochondrial membrane and emerged to play role in lipid metabolic reprogramming. This study aimed to elucidate the mechanistic role of SLC25A1 in lipid metabolic reprogramming and its therapeutic potential in HCC. METHODOLOGY AND
resultsIn the current study, enhanced expression of SLC25A1 gene was observed in toxicant induced mouse model of HCC suggesting a correlation with initiation and development of HCC. However, the precise mechanistic involvement of SLC25A1 in HCC is unclear underscoring the need of an in depth study. Clinical relevance of SLC25A1 in HCC was primarily evaluated using The Cancer Genome Atlas database. The in silico results not only demonstrated a strong correlation between the expression of SLC25A1 and HCC but also associated it with poor survival. In depth gain of function analysis using mammalian expression vector, SLC25A1-PCMV3 in human cell lines exhibited enhanced cellular growth, invasion, and migration potentials of cells expressing SLC25A1. Notably, the overexpression of SLC25A1 was associated with increased de novo lipogenesis, consistent with metabolic reprogramming favoring cytosolic citrate utilizationas evident by upregulation of FASN, ACACA, ACLY, SCD1 and downregulation of IDH2 and OGDH. Virtual screening and molecular docking studies presented rutin, a natural flavonoid, as a potential inhibitor of SLC25A1. In vitro inhibition of SLC25A1 by treatment with rutin significantly suppressed SLC25A1 expression leading to reduced lipogenesis.
conclusionCollectively, these findings propose SLC25A1 is associated with metabolic reprogramming in HCC and contribute to tumor progression.by promoting lipogenesis. Thus offering a promising therapeutic target for early intervention and treatment.
Indexed as
Identifiers
42467147What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.